Table 10.
Global clinical assessment by the investigator in the PP set (no assessment in 103 patients)
| Assessment | Investigator | Patient | ||
|---|---|---|---|---|
| Group | Nitroxoline (n = 148) | Controls (n = 158) | Nitroxoline (n = 148) | Controls (n = 158) |
| Very good | 115 (77.7%) | 138 (87.3%) | 109 (73.6%) | 123 (77.8%) |
| Good | 19 (12.8%) | 13 (8.2%) | 26 (17.6%) | 29 (18.4%) |
| Satisfactory | 4 (2.7%) | 5 (3.2%) | 5 (3.4%) | 4 (2.5%) |
| Moderate | 1 (0.7%) | 0 (0%) | 3 (2.0%) | 1 (0.6%) |
| Insufficient | 9 (6.1%) | 2 (1.3%) | 5 (3.4%) | 1 (0.6%) |
| p-value* | 0.006 | 0.143 | ||
*comparison of nitroxoline vs. controls (ordered probit regression with random center effect).